Newsletter May 2014
19 Feb 2015
WWARN Published Date
WWARN partners have set up a new study group to understand the affects artemisinin-based combination therapies can have on haemoglobin levels and malaria-related anaemia.- Researchers have worked together to build a comprehensive open-access database that provides an insight into the global scale and severity of falsified and substandard medicines.
- The WWARN QA/QC team are working in partnership with 48 labs from 26 different countries to strengthen the output of data on antimalarial treatment programmes during clinical trials.
- VecNet and WWARN are exploring the opportunity to share summarised data on drug efficacy and measures of resistance to antimalarials in a specific area. This combined information could be used in simulation models that might inform future vector and drug strategies.
- On April 25 2014, people from across the world supported World Malaria Day (WMD), a day dedicated to raising the profile of the global effort needed to control and eventually eradicate malaria.